Want to see TSHA full AI Analyst Report?
Taysha Gene Therapies (TSHA) Ownership - Who Owns Taysha Gene Therapies?
Taysha Gene Therapies (TSHA) Ownership Overview
- 2.88% Insiders
- 9.68% Mutual Funds
- 0.48% Other Institutional Investors
- 12.28% ETFs
- 74.68% Public Companies and Individual Investors
The ownership structure of Taysha Gene Therapies (TSHA) stock is a mix of institutional, retail, and individual investors. Approximately 22.44% of the company’s stock is owned by Institutional Investors, 2.88% is owned by Insiders, and 74.68% is owned by Public Companies and Individual Investors.
The ownership structure of Taysha Gene Therapies (TSHA) stock is a mix of institutional, retail, and individual investors. Approximately 10.16% of the company’s stock is owned by Institutional Investors, 2.88% is owned by Insiders, and 12.28% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Feb 05, 2026 | Kamran Alam | $7,481 | |
| Jan 26, 2026 | Sukumar Nagendran | $547,469 | |
| Jan 26, 2026 | Sean Nolan | $840,196 | |
| Jan 26, 2026 | Kamran Alam | $485,042 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|---|---|---|
| Jun 30, 2026 | Moore Capital Management Lp | $2,440,527 | |
| Jun 30, 2026 | Farallon Capital Management, L.l.c. | $15,322,500 | |
| Jun 30, 2026 | $140,912,023 |
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Peter Kolchinsky | 23,555,648 | Institution | 7.23% | 97,284,826 |
| Vanguard | 14,956,299 | Institution | 4.59% | 61,769,515 |
| Ishares | 13,148,110 | Institution | 4.04% | 54,301,694 |
| Vanguard Index Funds | 12,182,597 | Institution | 3.74% | 50,314,126 |
| Spdr | 6,742,189 | Institution | 2.07% | 27,845,241 |
| Fidelity Mt. Vernon Street Trust | 5,997,426 | Institution | 1.84% | 24,769,369 |
| Sean Nolan | 4,443,802 | Insider | 1.36% | 18,352,902 |
| Felix Baker | 4,004,756 | Institution | 1.23% | 16,539,642 |
| Fidelity Salem Street Trust | 2,887,288 | Institution | 0.89% | 11,924,499 |
| James E. Flynn | 2,722,165 | Institution | 0.84% | 11,242,541 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard Index Funds | 12,182,597 | Institution | 3.74% | 50,314,126 |
| Fidelity Mt. Vernon Street Trust | 5,997,426 | Institution | 1.84% | 24,769,369 |
| Fidelity Salem Street Trust | 2,887,288 | Institution | 0.89% | 11,924,499 |
| Fidelity Concord Street Trust | 2,631,454 | Institution | 0.81% | 10,867,905 |
| Vanguard Scottsdale Funds | 1,656,116 | Institution | 0.51% | 6,839,759 |
| Fidelity Select Portfolios | 940,476 | Institution | 0.29% | 3,884,166 |
| Schwab Capital Trust | 749,654 | Institution | 0.23% | 3,096,071 |
| Vanguard World Fund | 559,162 | Institution | 0.17% | 2,309,339 |
| Tiaa-cref Funds | 545,757 | Institution | 0.17% | 2,253,976 |
| Victory Portfolios Iii | 536,364 | Institution | 0.16% | 2,215,183 |
Top ETF Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard | 9,187,048 | Institution | 2.82% | 44,740,924 |
| iShares | 6,736,349 | Institution | 2.07% | 28,427,393 |
| SPDR | 5,370,112 | Institution | 1.65% | 22,661,873 |
| Vanguard | 3,059,631 | Institution | 0.94% | 14,900,403 |
| iShares | 2,510,499 | Institution | 0.77% | 10,368,361 |
| iShares | 2,064,528 | Institution | 0.63% | 8,526,501 |
| Vanguard | 1,551,256 | Institution | 0.48% | 7,554,617 |
| Schwab | 1,451,162 | Institution | 0.45% | 6,123,904 |
| Fidelity | 1,258,096 | Institution | 0.39% | 5,309,165 |
| Vanguard | 559,774 | Institution | 0.17% | 2,726,099 |
FAQ
Who Owns Taysha Gene Therapies (TSHA)?
According to the latest TipRanks data, approximately 0.48% of the company's stock is held by institutional investors, 2.88% is held by insiders, and 74.68% is held by retail investors.
What percentage of Taysha Gene Therapies (TSHA) stock is held by institutional investors?
According to the latest TipRanks data, approximately 0.48% of Taysha Gene Therapies (TSHA) stock is held by institutional investors.
What percentage of Taysha Gene Therapies (TSHA) stock is held by retail investors?
According to the latest TipRanks data, approximately 74.68% of Taysha Gene Therapies (TSHA) stock is held by retail investors.
Who owns the most shares of Taysha Gene Therapies (TSHA)?
Peter Kolchinsky owns the most shares of Taysha Gene Therapies (TSHA).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.